

Investor Webinar on Clinical Trial Results

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces an investor webinar to discuss the Company's Phase II/III autism spectrum disorder (ASD) clinical results and top-line Phase I/II Rett Syndrome clinical results.

Executive Director Dr Thomas Duthy will present at **12pm AEST on Wednesday 17 April 2024**.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: https://us02web.zoom.us/webinar/register/WN_emXuxVP_RP6tOAwA9WzwFQ

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels. Questions can be submitted in advance to matt@nwrcommunications.com.au

Further Information

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has completed recruitment for a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD and a Phase I/II trial in Rett Syndrome and reported Phase I/II clinical trial data in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS. In addition, Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.